- Open
- 4.97
- High
- 4.99
- Low
- 4.61
- Close
- 4.70
- Change
- -0.20 (-4.17%)
- Volume
- 1,896,407
⌘K
| 10 Apr 2026 | 07:00:04 | Holding(s) in Company |
| 9 Apr 2026 | 07:00:08 | Chairman’s Open Letter to Shareholders |
| 7 Apr 2026 | 11:45:21 | Result of General Meeting and TVR |
| 27 Mar 2026 | 07:00:05 | P140 Program Update |
| 23 Mar 2026 | 07:00:09 | Result of WRAP Retail Offer and TVR |
| 19 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 1 Jan 2025 | Annual Report December 2010 | |
| 1 Jan 2025 | Annual Report December 2011 |
ImmuPharma PLC is a London-based company with research facilities in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). Its primary focus is on creating groundbreaking medications to address critical health issues.
| 10 Apr 2026 | 07:00:04 | Holding(s) in Company |
| 9 Apr 2026 | 07:00:08 | Chairman’s Open Letter to Shareholders |
| 7 Apr 2026 | 11:45:21 | Result of General Meeting and TVR |
| 27 Mar 2026 | 07:00:05 | P140 Program Update |
| 23 Mar 2026 | 07:00:09 | Result of WRAP Retail Offer and TVR |
| 19 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 1 Jan 2025 | Annual Report December 2010 | |
| 1 Jan 2025 | Annual Report December 2011 |
ImmuPharma PLC is a London-based company with research facilities in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). Its primary focus is on creating groundbreaking medications to address critical health issues.
